Recursion Pharmaceuticals announced that Dr. Vicki Goodman will assume the role of Chief Medical Officer effective April 6 2026, succeeding Dr. David Mauro, M.D., Ph.D. Goodman brings more than two decades of oncology drug‑development experience, having led clinical programs at Mural Oncology, Exelixis, Merck, and Bristol Myers Squibb, and has served as an FDA reviewer.
Recursion is a clinical‑stage biotech that uses an AI‑driven platform to discover and develop medicines across oncology, rare disease, neuroscience, and immunology. The company has faced financial headwinds, reporting negative operating and net margins and declining revenue growth, but it maintains a strong balance sheet with $754 million in cash and low debt, providing runway into early 2028.
Goodman’s appointment is intended to strengthen Recursion’s clinical pipeline and accelerate the translation of its AI‑driven discoveries into approved therapies. Her deep expertise in late‑stage oncology and regulatory affairs is expected to help navigate critical clinical and regulatory inflection points, a priority highlighted by the company’s leadership.
Najat Khan, Ph.D., CEO and President, said, “We are very excited to welcome Dr. Goodman to Recursion. Vicki's depth of clinical development experience, sound judgment, and the clarity with which she approaches advancing programs through critical regulatory and clinical inflection points are the leadership skills that will help us advance our clinical pipeline.” She added, “This combination of experience, especially at the later stages of clinical development, will be invaluable as we translate scientific insight into disciplined, high‑quality programs and deliver differentiated medicines for patients.” Dr. Goodman echoed the sentiment, stating, “Recursion stands apart in the industry through its ambitious integration of scientific and technological rigor to reimagine how medicines are discovered and developed through the power of AI. I'm thrilled to join the company at such an important moment. I look forward to working with Najat, the leadership team, and the broader organization to advance the pipeline, support smart and disciplined development decisions, and help bring impactful new therapies to patients.” Dr. Mauro, the outgoing CMO, remarked, “Recursion has been a remarkable place to serve, and I'm proud of what we've built together over the past several years.”
The announcement was met with a cautious market reaction, reflecting concerns about Recursion’s financial challenges. The company’s negative margins and declining revenue growth have weighed on investor sentiment, even as its strong cash position and low debt provide a buffer for continued investment in its AI platform and clinical programs.
The appointment signals Recursion’s continued focus on translating its AI‑driven discoveries into clinical success. While the company’s financial metrics remain under pressure, the addition of Goodman’s regulatory and oncology expertise is expected to improve the efficiency and likelihood of advancing its pipeline, potentially enhancing long‑term value for stakeholders.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.